Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

doxycycline hyclate matrix formulation

An extended release (ER) formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, in a biodegradable, polymer-lipid encapsulation matrix (PLEX), with antimicrobial activity. Following reconstitution and administration in the surgical wound/incision, doxycycline is released from the matrix over an extended period of time. Upon release, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis. This may prevent surgical site infections.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:doxycycline hyclate matrix extended-release formulation
doxycycline polymer-lipid encapsulation matrix formulation
US brand name:D-PLEX
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search